Sanofi Seeks Chinese Partners For R&D Work
This article was originally published in PharmAsia News
Sanofi Aventis seeks to involve Chinese universities and laboratories in research partnerships by the end of this year, concentrating on cancer and rheumatoid arthritis treatments. The head of Sanofi's research and development said the company hopes the joint efforts with six Chinese institutions would help it discover new drugs. Marc Cluzel notes the Chinese government is investing in biological research and education he believes will make China a key resource for innovative new drugs by 2015. The Sanofi approach differs from other drug makers who plan to build R&D facilities in China. (Click here for more - a subscription may be required
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.